AT365581B - Verfahren zur herstellung neuer 2-benzyl-1,2dihydro-1-oxo-phthalazin-4-ylessigsaeurederivate und deren salze - Google Patents

Verfahren zur herstellung neuer 2-benzyl-1,2dihydro-1-oxo-phthalazin-4-ylessigsaeurederivate und deren salze

Info

Publication number
AT365581B
AT365581B AT0937678A AT937678A AT365581B AT 365581 B AT365581 B AT 365581B AT 0937678 A AT0937678 A AT 0937678A AT 937678 A AT937678 A AT 937678A AT 365581 B AT365581 B AT 365581B
Authority
AT
Austria
Prior art keywords
ylessigaic
2dihydro
phthalazine
oxo
benzyl
Prior art date
Application number
AT0937678A
Other languages
German (de)
English (en)
Other versions
ATA937678A (de
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Ltd filed Critical Ici Ltd
Priority to AT224481A priority Critical patent/AT366672B/de
Priority to AT224581A priority patent/AT366673B/de
Publication of ATA937678A publication Critical patent/ATA937678A/de
Application granted granted Critical
Publication of AT365581B publication Critical patent/AT365581B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT0937678A 1977-12-29 1978-12-29 Verfahren zur herstellung neuer 2-benzyl-1,2dihydro-1-oxo-phthalazin-4-ylessigsaeurederivate und deren salze AT365581B (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AT224481A AT366672B (de) 1977-12-29 1981-05-19 Verfahren zur herstellung neuer phthalazin-4-yl- essigsaeurederivate und von deren salzen
AT224581A AT366673B (de) 1977-12-29 1981-05-19 Verfahren zur herstellung neuer phthalazin-4ylessigs[uren und deren salze

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5414277 1977-12-29

Publications (2)

Publication Number Publication Date
ATA937678A ATA937678A (de) 1981-06-15
AT365581B true AT365581B (de) 1982-01-25

Family

ID=10470067

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0937678A AT365581B (de) 1977-12-29 1978-12-29 Verfahren zur herstellung neuer 2-benzyl-1,2dihydro-1-oxo-phthalazin-4-ylessigsaeurederivate und deren salze

Country Status (31)

Country Link
US (2) US4251528A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0002895B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPS5495582A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT365581B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU516264B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG34336A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1107732A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS241015B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1219A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD141021A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2861170D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK151253C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES476496A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI64357C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR65303B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK22484A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU182585B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE47592B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL56099A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN150196B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1110885B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY8500359A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO154346C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ189034A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH15435A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL118443B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT68956A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG68683G (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SU (3) SU1087075A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (3) YU41607B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZW (1) ZW24978A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
CA1143733A (en) * 1979-07-31 1983-03-29 Masao Yoshida Producing 7-alkoxycarbonyl-6,8-dimethyl-4- hydroxymethyl-1-phthalazone and intermediates
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
EP0222576B1 (en) * 1985-11-07 1992-03-18 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
US5011840A (en) * 1986-11-24 1991-04-30 Pfizer Inc. Imidazolidinedione derivatives in diabetes treatment
GB8704569D0 (en) * 1987-02-26 1987-04-01 Ici America Inc Therapeutic agent
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
EP0315249A1 (en) * 1987-11-02 1989-05-10 Merck & Co. Inc. Phthalazineacetic acid composition and tablet
DK607188A (da) * 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US4880928A (en) * 1987-12-21 1989-11-14 Merck & Co., Inc. Process for the preparation of 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-1-phthalazine-acetic acid
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4940791A (en) * 1988-02-29 1990-07-10 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
EP0397930A1 (en) * 1989-05-18 1990-11-22 Merck & Co. Inc. Process for the preparation of 3-[(4-bromo-2-fluorophenyl) methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
FI922308A0 (fi) * 1989-12-15 1992-05-21 Pfizer Substituerade oxoftalazinylaettiks- syror och deras analoger.
US5037831A (en) * 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
FR2682108B1 (fr) * 1991-10-07 1994-01-07 Lipha Acide 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetiques et derives, leurs preparations et medicaments les contenant.
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
EP0666851A4 (en) * 1992-11-02 1995-08-30 Merck & Co. Inc. Substituted phthalazinones as nerotensin antagonists.
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
AU7195594A (en) * 1993-07-26 1995-02-20 Fujisawa Pharmaceutical Co., Ltd. Oxophthalazines for treating cachexia
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
WO1998042324A2 (en) * 1997-03-21 1998-10-01 The Regents Of The University Of California Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
NZ516696A (en) * 1997-04-15 2003-08-29 Csir Pharmaceutical compositions having appetite suppressant activity
AU774929B2 (en) * 1998-03-31 2004-07-15 Institutes For Pharmaceutical Discovery, Llc, The Substituted indolealkanoic acids
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
KR20030059287A (ko) * 2000-11-30 2003-07-07 화이자 프로덕츠 인코포레이티드 Ｇａｂａ 작용제 및 알도스 리덕타제 억제제의 혼합물
DE60204611T2 (de) 2001-02-28 2006-05-11 Pfizer Products Inc., Groton Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren
DE60217930T2 (de) * 2001-03-30 2007-10-18 Pfizer Products Inc., Groton Pyridazinon Aldose Reductase Inhibitoren
JP2004528344A (ja) * 2001-04-30 2004-09-16 ファイザー・プロダクツ・インク アルドースレダクターゼ阻害薬とシクロオキシゲナーゼ−２阻害薬の併用
AU761191B2 (en) 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US20050209237A1 (en) * 2002-04-30 2005-09-22 Brazzell Romulus K Method for decreasing capillary permeability in the retina
JP2006500336A (ja) * 2002-07-26 2006-01-05 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 糖尿病合併症の処置に使用するための置換インドールアルカン酸誘導体及びそれを含む製剤。
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
JP4838582B2 (ja) * 2004-12-27 2011-12-14 岐阜プラスチック工業株式会社 台車用本体
JP2010520913A (ja) 2007-03-12 2010-06-17 サズセ アーペーエス ルイボスの抗糖尿病性抽出物
CA2685202C (en) 2007-03-23 2017-11-28 The Board Of Regents Of The University Of Texas System Methods for treating allergic asthma
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CA2822672C (en) 2010-12-23 2018-06-05 The Board Of Regents Of The University Of Texas System Methods for treating copd
MX372739B (es) 2012-12-14 2020-05-06 Phusis Therapeutics Inc Metodos y composiciones para inhibir cnksr1.
US10227356B2 (en) 2015-04-20 2019-03-12 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting CNKSR1
WO2019165195A1 (en) 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer
CN112789149B (zh) * 2018-10-04 2023-06-06 日东电工株式会社 耐热脱模片和热压接方法
JP6751974B1 (ja) * 2019-10-16 2020-09-09 株式会社コバヤシ 離型フィルム及び離型フィルムの製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833579A (en) * 1935-11-11 1974-09-03 Inoue Michiro 4-carbamoyl phthalazones
JPS5116430B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1971-08-05 1976-05-24
GB1398549A (en) * 1972-11-06 1975-06-25 Boots Co Ltd Phthalazine derivatives and their use in pharmaceutical compo sitions
AR205004A1 (es) * 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona
DE2451117A1 (de) * 1973-10-31 1975-05-22 Boots Co Ltd Therapeutisch wirksame verbindungen
GB1502312A (en) 1975-03-20 1978-03-01 Ici Ltd Quinolone derivatives
IE43079B1 (en) * 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
JPS5214788A (en) * 1975-07-21 1977-02-03 Fuji Photo Film Co Ltd Process for preparing phthalazinone and its derivatives
NL7702763A (nl) * 1976-03-18 1977-09-20 Takio Shimamoto En Masayuki Is Werkwijze voor de bereiding van thromboxaan- -antagonisten en van preparaten die deze stof- fen bevatten.
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4293553A (en) * 1978-08-11 1981-10-06 Masayuki Ishikawa 1-Phthalazone derivatives, and use thereof

Also Published As

Publication number Publication date
DK541878A (da) 1979-06-30
SU1272984A3 (ru) 1986-11-23
NZ189034A (en) 1981-11-19
IT7852480A0 (it) 1978-12-28
YU42054B (en) 1988-04-30
SU1072803A3 (ru) 1984-02-07
JPS6326110B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1988-05-27
FI783844A7 (fi) 1979-06-30
DD141021A5 (de) 1980-04-09
PL118443B1 (en) 1981-10-31
NO784397L (no) 1979-07-02
SG68683G (en) 1984-08-03
HK22484A (en) 1984-03-23
US4251528A (en) 1981-02-17
YU42807B (en) 1988-12-31
EP0002895B1 (en) 1981-10-14
JPH0262532B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-12-26
ES476496A1 (es) 1979-04-16
SU1087075A3 (ru) 1984-04-15
IE782337L (en) 1979-06-29
AU4204078A (en) 1979-07-05
YU312778A (en) 1983-01-21
YU232082A (en) 1983-01-21
IE47592B1 (en) 1984-05-02
CS241015B2 (en) 1986-03-13
HU182585B (en) 1984-02-28
GR65303B (en) 1980-08-01
JPS63119469A (ja) 1988-05-24
NO154346C (no) 1986-09-03
DE2861170D1 (en) 1981-12-24
MY8500359A (en) 1985-12-31
PT68956A (en) 1979-01-01
DK151253C (da) 1988-05-16
EP0002895A1 (en) 1979-07-11
CY1219A (en) 1984-04-06
AU516264B2 (en) 1981-05-28
IN150196B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-08-14
PH15435A (en) 1983-01-18
FI64357B (fi) 1983-07-29
YU41607B (en) 1987-12-31
YU232182A (en) 1983-01-21
ATA937678A (de) 1981-06-15
FI64357C (fi) 1983-11-10
JPS5495582A (en) 1979-07-28
NO154346B (no) 1986-05-26
ZW24978A1 (en) 1980-10-22
US4393062A (en) 1983-07-12
DK151253B (da) 1987-11-16
IT1110885B (it) 1986-01-06
IL56099A0 (en) 1979-01-31
BG34336A3 (bg) 1983-08-15
CA1107732A (en) 1981-08-25

Similar Documents

Publication Publication Date Title
AT365581B (de) Verfahren zur herstellung neuer 2-benzyl-1,2dihydro-1-oxo-phthalazin-4-ylessigsaeurederivate und deren salze
AT365589B (de) Verfahren zur herstellung neuer 4-hydroxy-2h-1,2benzothiazin-3-carboxamid-1,1-dioxide und deren salze
AT365187B (de) Verfahren zur herstellung neuer 3-(1h-tetrazol-5yl)-hh-pyrido(1,2-a)-pyrimidin-4-one und von derensalzen
ATA936176A (de) Verfahren zur herstellung neuer, basisch substituierter indolderivate und deren saeure- additionssalze
AT361929B (de) Verfahren zur herstellung neuer 5,11-dihydro- -6h-pyrido(2,3-b)(1,4) benzodiazepin-6-on- -derivate und ihrer salze
AT380020B (de) Verfahren zur herstellung von d,1-5-methyltetrahydrofols|ureund deren salzen
AT364821B (de) Verfahren zur herstellung neuer indole, deren saeureadditionssalze und deren isomere
ATA863478A (de) Verfahren zur herstellung neuer 1,4-benzodiazepin-derivate und ihrer salze
AT360028B (de) Verfahren zur herstellung neuer, 5-piperazinyl- substituierter derivate von pyrido-(2.3-b)- -benzothiazepin(1.5) und ihrer salze
AT375369B (de) Verfahren zur herstellung neuer 1,2,4-oxadiazolin-5-on-derivate sowie von deren salzen
AT375069B (de) Verfahren zur herstellung der (2,2-dimethyl-1,2dihydro-chinolin-4-yl)-methyl-sulfon-s[ure und von deren salzen
ATA63479A (de) Verfahren zur herstellung neuer 3,4-dihydro-2h-1,2-benzothiazin-1,1-dioxyde und deren salzen
ATA407977A (de) Verfahren zur herstellung neuer hydrazinopyridazinderivate und deren salzen
AT369738B (de) Verfahren zur herstellung neuer thiodibenzoxepine und deren saeureadditionssalze
AT361916B (de) Verfahren zur herstellung neuer 3-imino-9,9a- dihydrothiazolo(3,4-a)indolderivate und ihrer salze
ATA678478A (de) Verfahren zur herstellung von neuen 4-alkyl-3,5-dioxo-pyrazolidinylderivaten und von deren salzen
AT357519B (de) Verfahren zur herstellung neuer, basisch substituierter indolderivate und deren saeure- additionssalze
AT358731B (de) Verfahren zur herstellung von cyanacetamid- -derivaten und deren salzen
AT360040B (de) Verfahren zur herstellung von substituierten orotsaeuren, dihydroorotsaeuren und deren salzen
ATA429979A (de) Verfahren zur herstellung neuer 2,3-dihydro- -2-oxothiophenderivate und ihrer salze
ATA165480A (de) Verfahren zur herstellung neuer benz-acylbenzimidazol-2-derivate und deren salze
AT356116B (de) Verfahren zur herstellung neuer derivate des pyrrolo-(1,2-a) (1,4)-diazepines und deren salzen
ATA263282A (de) Verfahren zur herstellung neuer 2-pyridylaminobenzoes[ure und ihrer salze
ATA46183A (de) Verfahren zur herstellung neuer 2-pyridylaminobenzoesaeuren und ihre salze
AT371115B (de) Verfahren zur herstellung neuer 1,2,3,4-tetrahydro-2-piperazinyl-naphthaline und ihrer saeureadditionssalze

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee